rf-fullcolor.png

 

April 15, 2013
by Alexander Gaffney, RAC

Preview: Supreme Court Could Determine Biotechnology Industry's Future

Depending upon whom you ask, a case to be heard by the US Supreme Court on Monday will either mark a massive blow to the biotechnology industry and its regulated products or a massive blow to the practice of science, including the ability to use a genetic marker to determine the best course of treatment for a patient. Regardless of the veracity of either side's claim, one thing is clear: the case of Association for Molecular Pathology, et al vs. Myriad Genetics will be enormously important.

Background

The case concerns two well-known genetic patents used in the detection of breast and ovarian cancer, BRCA1 and BRCA2, held by Myriad Genetics, a biotechnology company.

Unlike other patents, where a company might own rights to the patent in its use in a particular diagnostic tool or therapeutic treatment, Myriad patented the genes directly. That's raised some novel-and to some, troubling-legal questions regarding whether those patents ought to be valid.

At issue: Is the genetic code of the human body a patentable entity? If not, will incentives exist to permit investment in the biopharmaceutical and biotechnology sectors? May a patent on a single gene control or prohibit all derivative works in that area?

Difficult questions, all, and ones set to go before the court on 10 a.m. EST on Monday, 15 April 2013.

Essential Reading

  • Argument preview: The right to study genes (SCOTUS Blog)
  • Case History: Association for Molecular Pathology v. Myriad Genetics, Inc. (SCOTUS Blog)
  • Supreme Court wrestles with right to patent human genes (The Hill)
  • Appeals Court Decision from August 2012 (Case)
  • U.S. top court weighs patentability of human genes (Reuters)
  • Will the Supreme Court end human gene patents after three decades? (Ars Technica)
  • Myriad hinges on semantic strategies (SCRIP Intelligence) ($)
  • Justices Consider Whether Patents on Genes Are Valid (NYTimes)
  • Gene Patents: Supreme Court Could Be Swayed By Impact On Research (The Pink Sheet) ($)
  • Supreme Court gene patent decision could affect every patient (NBC)
  • Can human genes be patented? Supreme Court weighs genetic test (NBC)
×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.